Mark Lipphardt

802 total citations
18 papers, 532 citations indexed

About

Mark Lipphardt is a scholar working on Molecular Biology, Nephrology and Critical Care and Intensive Care Medicine. According to data from OpenAlex, Mark Lipphardt has authored 18 papers receiving a total of 532 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 3 papers in Nephrology and 3 papers in Critical Care and Intensive Care Medicine. Recurrent topics in Mark Lipphardt's work include Renal and related cancers (5 papers), Blood Pressure and Hypertension Studies (3 papers) and Heme Oxygenase-1 and Carbon Monoxide (3 papers). Mark Lipphardt is often cited by papers focused on Renal and related cancers (5 papers), Blood Pressure and Hypertension Studies (3 papers) and Heme Oxygenase-1 and Carbon Monoxide (3 papers). Mark Lipphardt collaborates with scholars based in Germany, United States and South Korea. Mark Lipphardt's co-authors include Michael S. Goligorsky, Jong Wook Song, Gerhard A. Müller, Brian B. Ratliff, Hassan Dihazi, Joseph Zullo, Xiao Hui Zhang, Dong Sun, Michael Koziolek and Manuel Wallbach and has published in prestigious journals such as Kidney International, Developmental Biology and American Journal of Physiology-Heart and Circulatory Physiology.

In The Last Decade

Mark Lipphardt

18 papers receiving 524 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Lipphardt Germany 14 158 87 77 76 73 18 532
Reny Joseph United States 9 503 3.2× 68 0.8× 131 1.7× 91 1.2× 19 0.3× 10 877
Vincent Fridén Sweden 12 190 1.2× 101 1.2× 179 2.3× 116 1.5× 24 0.3× 14 830
Miguel Fragoso United States 17 134 0.8× 305 3.5× 33 0.4× 44 0.6× 67 0.9× 35 719
Hirotaka Imamaki Japan 10 207 1.3× 57 0.7× 362 4.7× 70 0.9× 19 0.3× 19 702
H.‐P. Schultheiss Germany 9 154 1.0× 41 0.5× 130 1.7× 57 0.8× 23 0.3× 14 735
Martijn J. C. Dane Netherlands 8 98 0.6× 230 2.6× 220 2.9× 42 0.6× 53 0.7× 8 622
İbrahim Meteoğlu Türkiye 16 135 0.9× 16 0.2× 56 0.7× 35 0.5× 62 0.8× 72 688
Maria Varoudi Greece 14 96 0.6× 46 0.5× 26 0.3× 147 1.9× 20 0.3× 23 655
Jurong Yang China 11 354 2.2× 49 0.6× 366 4.8× 109 1.4× 18 0.2× 13 890
Marina Goldfarb Israel 13 177 1.1× 55 0.6× 353 4.6× 19 0.3× 95 1.3× 19 715

Countries citing papers authored by Mark Lipphardt

Since Specialization
Citations

This map shows the geographic impact of Mark Lipphardt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Lipphardt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Lipphardt more than expected).

Fields of papers citing papers by Mark Lipphardt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Lipphardt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Lipphardt. The network helps show where Mark Lipphardt may publish in the future.

Co-authorship network of co-authors of Mark Lipphardt

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Lipphardt. A scholar is included among the top collaborators of Mark Lipphardt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Lipphardt. Mark Lipphardt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Lipphardt, Mark, et al.. (2021). Eligibility for Baroreflex Activation Therapy and medication adherence in patients with apparently resistant hypertension. Journal of Clinical Hypertension. 23(7). 1363–1371. 3 indexed citations
2.
Lipphardt, Mark, Jong Wook Song, & Michael S. Goligorsky. (2020). Sirtuin 1 and endothelial glycocalyx. Pflügers Archiv - European Journal of Physiology. 472(8). 991–1002. 19 indexed citations
3.
Rudnicki, Michael, Justyna Siwy, Heather N. Reich, et al.. (2020). MO041URINE PROTEOMICS FOR PREDICTION OF DISEASE PROGRESSION IN PATIENTS WITH IGA NEPHROPATHY. Nephrology Dialysis Transplantation. 35(Supplement_3). 5 indexed citations
4.
Lipphardt, Mark, Manuel Wallbach, & Michael Koziolek. (2020). Plasma Exchange or Immunoadsorption in Demyelinating Diseases: A Meta-Analysis. Journal of Clinical Medicine. 9(5). 1597–1597. 22 indexed citations
5.
Lipphardt, Mark, Hassan Dihazi, J.H. Maas, et al.. (2020). Syndecan-4 as a Marker of Endothelial Dysfunction in Patients with Resistant Hypertension. Journal of Clinical Medicine. 9(9). 3051–3051. 17 indexed citations
6.
Lipphardt, Mark, et al.. (2019). Effect of baroreflex activation therapy on renal sodium excretion in patients with resistant hypertension. Clinical Research in Cardiology. 108(11). 1287–1296. 5 indexed citations
7.
Lipphardt, Mark, Bernd Kitze, Franz Heigl, et al.. (2019). Immunoadsorption or plasma exchange in steroid‐refractory multiple sclerosis and neuromyelitis optica. Journal of Clinical Apheresis. 34(4). 381–391. 39 indexed citations
8.
Rabadi, May M., Sanjeev Gupta, Stephen Chen, et al.. (2018). Maternal malnourishment induced upregulation of fetuin-B blunts nephrogenesis in the low birth weight neonate. Developmental Biology. 443(1). 78–91. 11 indexed citations
9.
Lipphardt, Mark, Hassan Dihazi, Gerhard A. Müller, & Michael S. Goligorsky. (2018). Fibrogenic Secretome of Sirtuin 1-Deficient Endothelial Cells: Wnt, Notch and Glycocalyx Rheostat. Frontiers in Physiology. 9. 1325–1325. 23 indexed citations
10.
Zhang, Xiao Hui, Dong Sun, Jong Wook Song, et al.. (2018). Endothelial cell dysfunction and glycocalyx – A vicious circle. Matrix Biology. 71-72. 421–431. 123 indexed citations
11.
Lipphardt, Mark, Hassan Dihazi, Noo Li Jeon, et al.. (2018). Dickkopf-3 in aberrant endothelial secretome triggers renal fibroblast activation and endothelial–mesenchymal transition. Nephrology Dialysis Transplantation. 34(1). 49–62. 43 indexed citations
12.
Shen, Michael, Joseph Zullo, Mark Lipphardt, et al.. (2017). Low birth weight is associated with impaired murine kidney development and function. Pediatric Research. 82(2). 340–348. 20 indexed citations
13.
Patel, Devika, et al.. (2017). HMGB1 redox during sepsis. Redox Biology. 13. 600–607. 64 indexed citations
14.
Lipphardt, Mark, Jong Wook Song, Kei Matsumoto, et al.. (2017). The third path of tubulointerstitial fibrosis: aberrant endothelial secretome. Kidney International. 92(3). 558–568. 38 indexed citations
15.
Song, Jong Wook, Joseph Zullo, Mark Lipphardt, et al.. (2017). Endothelial glycocalyx—the battleground for complications of sepsis and kidney injury. Nephrology Dialysis Transplantation. 33(2). 203–211. 32 indexed citations
16.
Lipphardt, Mark, Jong Wook Song, Brian B. Ratliff, et al.. (2017). Endothelial dysfunction is a superinducer of syndecan-4: fibrogenic role of its ectodomain. American Journal of Physiology-Heart and Circulatory Physiology. 314(3). H484–H496. 35 indexed citations
17.
Matsumoto, Kei, Sandhya Xavier, Jun Chen, et al.. (2016). Instructive Role of the Microenvironment in Preventing Renal Fibrosis. Stem Cells Translational Medicine. 6(3). 992–1005. 19 indexed citations
18.
Lipphardt, Mark, Mustafa Deryal, Mei Fang Ong, Werner Schmidt, & Ulrich Mahlknecht. (2013). ESR1 single nucleotide polymorphisms predict breast cancer susceptibility in the central European Caucasian population.. PubMed. 6(4). 282–8. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Reny Joseph Breakdown of academic impact, for papers by Vincent Fridén Breakdown of academic impact, for papers by Miguel Fragoso Breakdown of academic impact, for papers by Hirotaka Imamaki Breakdown of academic impact, for papers by H.‐P. Schultheiss Breakdown of academic impact, for papers by Martijn J. C. Dane Breakdown of academic impact, for papers by İbrahim Meteoğlu Breakdown of academic impact, for papers by Maria Varoudi Breakdown of academic impact, for papers by Jurong Yang Breakdown of academic impact, for papers by Marina Goldfarb
Rankless by CCL
2026